Drug Profile
AXA 1665
Alternative Names: AXA-1665Latest Information Update: 06 Dec 2023
Price :
$50
*
At a glance
- Originator Axcella Health
- Class Amino acids; Hepatoprotectants
- Mechanism of Action Metabolism-modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Hepatic encephalopathy
Most Recent Events
- 04 Dec 2023 Axcella Health winds down its business and remains no longer active
- 04 Dec 2023 Discontinued - Phase-II for Hepatic encephalopathy in Canada, Hungary, Italy, Poland, Spain, USA (PO)
- 27 May 2022 Axcella Therapeutics terminates a phase-II clinical trial in Hepatic encephalopathy in USA, Spain, Poland, Italy, Hungary and Canada (PO), to focus on other programs (NCT04816916)